Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.

Abstract

Ranpirnase (Onconase) is a novel cytotoxic ribonuclease. In clinical development as a single agent in patients with malignant mesothelioma (MM), at 480 microg/m2 intravenously weekly, analysis of survival indicated prolonged periods of stable disease in Phase II trials and a potential survival benefit, compared with doxorubicin, in a small unpublished Phase III trial. In all clinical studies it has generally demonstrated a favourable safety profile except for easily controlled allergic reactions and dose modifications for renal impairment. Standard first-line treatment for MM has recently been established with an antifolate and cisplatin. At present, a Phase III trial of doxorubicin with or without ranpirnase is nearing completion in MM patients without prior chemotherapy or one prior chemotherapy regimen.

• Authors: Nick Pavlakis, Nicholas J Vogelzang
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 6 Issue 4 Pg. 391-9 (Apr 2006) ISSN: 1744-7682 [Electronic] England
• PMID: 16548765 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Drugs, Investigational
• Ribonucleases
• ranpirnase

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Drugs, Investigational (therapeutic use)
• Humans
• Mesothelioma (drug therapy, enzymology)
• Ribonucleases (therapeutic use)